Novo's FlexPen injector has lower force than competitors

New data published in Expert Opinion Pharmacotherapy has revealed that the Next Generation FlexPen, Novo Nordisk's prefilled insulin delivery  device, has a significantly-lower injection force than two other  devices, French drug major Sanofi-Aventis' SoloStar and the USA's Eli  Lilly KwikPen.

The study revealed that the injection (dose) force of FlexPen was  12%-25% lower than SoloStar and 35%-41% lower than KwikPen. In addition,  Novo says this study and others have shown that FlexPen has advantages  over SoloStar and KwikPen in providing improved accuracy.

The study compared the dose forces of Next Generation FlexPen, SoloStar  and KwikPen by injecting 20U of insulin using two different gauge  needles (NovoFine 32G and BD Micro-fine 31G). Pens of each type were  tested at injection speeds of 3.3, 5.0 and 8.3mm/sec. At all three  injection speeds and with both needles, Next Generation FlexPen had a  significantly-lower average injection force than either SoloStar or  KwikPen, whilst KwikPen had the highest mean injection force.